Grid Therapeutics Announces Enrollment of First Patient in Phase 1 Study of GT103 in Refractory NSCLC Patients Read More…
Tumour extracellular vesicle‐derived Complement Factor H promotes tumorigenesis and metastasis by inhibiting complement‐dependent cytotoxicity of tumour cells